Lincluden Management LTD Has Cut Its Teva Pharmaceutical Inds LTD (TEVA) Position; Salem Investment Counselors Has Raised Boston Scientific Co. (BSX) Position

November 15, 2017 - By Clifton Ray

Salem Investment Counselors Inc increased Boston Scientific Co. (BSX) stake by 13.65% reported in 2017Q2 SEC filing. Salem Investment Counselors Inc acquired 13,973 shares as Boston Scientific Co. (BSX)’s stock rose 4.02%. The Salem Investment Counselors Inc holds 116,373 shares with $3.23M value, up from 102,400 last quarter. Boston Scientific Co. now has $38.89 billion valuation. The stock decreased 0.46% or $0.13 during the last trading session, reaching $28.32. About shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since November 15, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Lincluden Management Ltd decreased Teva Pharmaceutical Inds Ltd. (TEVA) stake by 32.42% reported in 2017Q2 SEC filing. Lincluden Management Ltd sold 26,695 shares as Teva Pharmaceutical Inds Ltd. (TEVA)’s stock declined 15.11%. The Lincluden Management Ltd holds 55,634 shares with $1.85 million value, down from 82,329 last quarter. Teva Pharmaceutical Inds Ltd. now has $11.95 billion valuation. The stock declined 1.11% or $0.13 reaching $11.62 per share. About 36,444 shares traded. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since November 15, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.




Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on February, 12. They expect $0.90 EPS, down 33.82% or $0.46 from last year’s $1.36 per share. TEVA’s profit will be $925.56 million for 3.23 P/E if the $0.90 EPS becomes a reality. After $0.95 actual EPS reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth.

Lincluden Management Ltd increased Bce Inc stake by 33,431 shares to 1.39M valued at $64.36M in 2017Q2. It also upped Cisco Systems Inc. (NASDAQ:CSCO) stake by 18,241 shares and now owns 438,016 shares. Canadian Imperial Bank Of Commerce (NYSE:CM) was raised too.

Among 31 analysts covering Teva Pharma (NYSE:TEVA), 8 have Buy rating, 7 Sell and 16 Hold. Therefore 26% are positive. Teva Pharma has $86 highest and $8 lowest target. $32.78’s average target is 182.10% above currents $11.62 stock price. Teva Pharma had 111 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Monday, October 30 by RBC Capital Markets. The rating was maintained by Barclays Capital on Friday, October 20 with “Equal-Weight”. The firm has “Equal-Weight” rating given on Wednesday, October 4 by Barclays Capital. The firm has “Outperform” rating by Cowen & Co given on Wednesday, April 5. The stock has “Buy” rating by Bank of America on Tuesday, January 31. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Equal-Weight” rating given on Wednesday, November 16 by Morgan Stanley. Jefferies maintained it with “Hold” rating and $21.0 target in Tuesday, September 12 report. Maxim Group maintained the shares of TEVA in report on Friday, August 4 with “Hold” rating. As per Monday, December 7, the company rating was initiated by Mizuho. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Goldman Sachs on Monday, November 23.

Since May 17, 2017, it had 0 insider buys, and 4 selling transactions for $1.16 million activity. Phalen Michael P. also sold $422,369 worth of Boston Scientific Corporation (NYSE:BSX) on Tuesday, May 30. 13,562 shares were sold by Pierce David A, worth $379,736. $271,261 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Pratt Timothy A. on Thursday, June 1. Another trade for 28,864 shares valued at $754,454 was sold by Ballinger Kevin J..

Among 28 analysts covering Boston Scientific Corporation (NYSE:BSX), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Boston Scientific Corporation had 70 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Tuesday, October 31 by SunTrust. The firm has “Buy” rating by RBC Capital Markets given on Monday, October 2. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by Stifel Nicolaus on Tuesday, August 1. Oppenheimer maintained Boston Scientific Corporation (NYSE:BSX) on Wednesday, June 28 with “Hold” rating. The firm has “Buy” rating given on Thursday, August 31 by Needham. The firm has “Neutral” rating by Wedbush given on Thursday, April 28. The company was maintained on Monday, September 25 by Stifel Nicolaus. The firm earned “Buy” rating on Friday, February 3 by Needham. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Hold” rating by BTIG Research on Monday, June 26. The firm has “Hold” rating by Oppenheimer given on Monday, May 1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.